Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
March 20, 2015

Recent Stories of Interest

From Drug Benefit News - Amid rising drug costs due to a multitude of factors (see story, p. 3), payers this month were given something to cheer about as the first U.S. biosimilar completed the accelerated approval pathway authorized by the Affordable Care Act. But the March 6 approval of Zarxio (filgrastim-sndz) — a copycat version of Amgen Inc.’s Neupogen (filgrastim) for the treatment of infection in certain cancer patients undergoing chemotherapy — was marked by several unknowns, starting with when it will actually hit the market and at what cost. Read more

Building on an ongoing effort to improve medication use in certain patient… Read more

After pulling back last year on a controversial proposal that would have… Read more

As the first generic version of AstraZeneca’s popular proton pump inhibitor Nexium… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

March 20, 2015
Judge Clears Way for First Biosimilar Launch

Judge declines to grant Amgen’s request for injunction to prevent Sandoz biosimilar Zarxio from launching; reference drug is Amgen’s Neupogen http://www.fdalawblog.net/NEUPOGEN%20-%20Opinion%20PI%20Denial.pdf

March 19, 2015
Senators Propose Medication Management Program for Seniors

Proposed legislation would expand seniors’ access to MTM services. http://tinyurl.com/o5322ku

March 10, 2015
Express Scripts: Drug Prices Rose 13% in 2014

Hepatitis C and compounded medicine drove a 13.1% rise in overall drug expenditures in 2014, says Express Scripts. http://tinyurl.com/o338ort

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?